Glioblastoma is one of the most aggressive and lethal types of brain tumours. Radiotherapy remains a cornerstone of treatment; however, its effectiveness is often limited by the risk of damaging the surrounding healthy brain tissue. Within the NuCapCure project, we are developing innovative compounds designed to exploit the tumour’s own biosynthetic machinery. These agents effectively turn cancer cells into intracellular “mini‑chemistry laboratories,” forcing them to produce therapeutic drugs from within. The compounds are then further activated by proton therapy, an advanced and highly precise form of radiotherapy. The NuCapCure agents will be validated and optimised using 2D and 3D glioblastoma cell culture models, after which the most promising candidates will be selected for in vivo evaluation. This approach has the potential to selectively target tumour cells while minimising damage to surrounding healthy brain tissue. The project offers a highly multidisciplinary research environment, including physics, chemistry and cancer biology. The appointed post‑doctoral researcher will play a central role in validating selected compounds in vivo, with a particular focus on assessing therapeutic responses in glioblastoma models.
More information about the NuCapCure project can be found here: https://nucapcure.eu
We are looking for an excellent and highly motivated post‑doctoral candidate with strong laboratory skills, preferably with a background in brain tumour biology, neuroscience, in‑vivo modelling, or related fields.
#J-18808-Ljbffr€45000 - €55000 monthly